TY - JOUR T1 - Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 69 LP - 72 DO - 10.2967/jnumed.120.242875 VL - 62 IS - 1 AU - Jonathan R. Strosberg AU - Taymeyah Al-Toubah AU - Eleonora Pellè AU - Johnna Smith AU - Mintallah Haider AU - Tai Hutchinson AU - Jason B. Fleming AU - Ghassan El-Haddad Y1 - 2021/01/01 UR - http://jnm.snmjournals.org/content/62/1/69.abstract N2 - Although radiation-induced mesenteritis or peritonitis can potentially exacerbate the risk of bowel obstruction, there are no data in the literature on the incidence of intestinal obstruction related to peptide receptor radionuclide therapy. Methods: The records of all patients treated with 177Lu-DOTATATE at Moffitt Cancer Center between April 2018 and October 2019 were evaluated. The number of patients who developed bowel obstruction within 3 mo of a 177Lu-DOTATATE treatment was divided by the total number of patients with preexisting peritoneal or mesenteric disease. Management strategies and outcomes were evaluated. Results: Of a total of 159 patients treated, 81 had baseline mesenteric or peritoneal disease, among whom 5 (6%) experienced at least 1 episode of bowel obstruction within 3 mo of treatment. Two of the patients underwent surgical exploration during obstruction describing a “frozen abdomen.” All 5 responded at least temporarily to high-dose corticosteroid treatment and regained bowel function, but 2 patients eventually succumbed to progressive peritoneal disease. Conclusion: Peptide receptor radionuclide therapy can lead to bowel obstruction in patients with mesenteric or peritoneal disease, likely by inducing inflammation. Corticosteroids can potentially play a role in treatment and prophylaxis. ER -